when will eli lilly glp 1 pill be available FDA approves Lilly's new weight loss Foundayo New GLP-1 Pill Foundayo (Orforglipron)

Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline

FAERS, FDA Adverse Event Reporting System

Vokinger KN, Nussli E, Dusetzina SB

FDA, the laboratory contributes to research efforts that bridge academic investigation and regulatory science